# What a randomized trial found in patients with endometriosis and poor ovarian response

- Article ID: research-170
- Product: HCG (hcg-683)
- Canonical page: https://heritagebiolabs.com/research-library/articles/170-what-a-randomized-trial-found-in-patients-with-endometriosis-and-poor-ovarian-response
- Product collection: https://heritagebiolabs.com/research-library/products/hcg
- Product page: https://heritagebiolabs.com/product/hcg-683
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2023, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds, and some carry hormonal signals. Human chorionic gonadotropin, abbreviated hCG, is a larger hormone built from two amino-acid chains with attached sugars. This makes it a glycoprotein. A 2026 trial asked whether adding a second hormone signal to a recombinant hCG trigger changed egg maturation in a defined group of fertility patients. [1, 2]

The participants had endometriosis and had met a study definition of poor ovarian response. They were undergoing intracytoplasmic sperm injection (ICSI), in which an embryologist places a sperm directly into a mature egg. Before retrieval, a trigger provides a signal for eggs to finish maturing. Both groups received recombinant hCG, which activates the same ovarian receptor as luteinizing hormone. One group also received a gonadotropin-releasing hormone agonist, which can prompt the pituitary gland to release its own hormones. The other group received a matching placebo for that additional intervention. [1, 2]

The researchers randomized 152 people. Of these, 128 completed the study protocol through embryo transfer. The primary endpoint was the number of eggs at metaphase II, the stage of maturity needed for ICSI. The group given both triggers had an average of about 6.5 mature eggs compared with about 4.1 in the hCG-only group. The authors also observed more top-graded embryos and higher clinical pregnancy rates in the group assigned both triggers. The trial distinguished outcomes among participants who completed the protocol from analyses that retained people according to their original group assignments. [1]

The endpoints occur at different stages. A mature egg can be fertilized but may never become a transferable embryo. An embryo can be transferred without producing an ongoing pregnancy, and a clinical pregnancy can end before live birth. The study measured egg and embryo outcomes and reported clinical pregnancy. Its findings cannot establish a live-birth advantage from the published outcomes. The result is also tied to the study's eligibility criteria, which selected for endometriosis and poor ovarian response. People with different diagnoses or different patterns of ovarian response might experience different results. [1]

The U.S. label for recombinant hCG covers specified fertility indications. The trial compared two approaches within a specific ICSI population and measured what adding the agonist changed in that setting. Its findings do not broaden the product's approval to every trigger combination or establish that the same comparison will give the same result in all fertility programs. [1, 2]

## Sources

1. Davari Tanha F et al. Recombinant hCG versus dual triggering for final oocyte maturation in ICSI cycles among poor responders with endometriosis. Reproduction and Fertility (publication 2026-10-01). <https://pubmed.ncbi.nlm.nih.gov/42782241/>
2. EMD Serono. OVIDREL- choriogonadotropin alfa injection, solution. U.S. prescribing information on DailyMed (updated 2023-12-26). <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a683e58a-63ea-44b8-a326-1a99a537bcf2>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 034 - Glutathione and HCG.docx; article 170; content SHA-256 840d622f21897af3c43c145f1d43f6bfd4631b7606cb200b9fbcdb0dae2fb620.
